Clinical Study
Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves’ Orbitopathy
Table 1
Baseline characteristics of patients.
| Characteristic | |
| Demographic and clinical characteristics | | Age (yr) | 43.38 ± 11.82 | Gender (female) | 3 (23.1%) | Weight (kg) | 68.08 ± 12.87 | Smoking history | | Current smoker | 6 (46.2%) | Ex-smoker | 1 (7.6%) | Never-smoker | 6 (46.2%) | History of thyroid disease | | Graves’ hyperthyroidism | 9 (69.2%) | Euthyroid Graves’ disease | 4 (30.8%) | Others | 0 (0%) | Previous antithyroid treatments | | Antithyroid drugs | 5 (55.6%) | Radioiodine | 1 (11.1%) | Thyroidectomy | 3 (33.3%) | Duration of Graves’ disease (months) | 15 (6–24) | Duration of Graves’ orbitopathy (months) | 6 (3–12) | Duration of euthyroidism (months) | 3 (1.5–3.5) | Biochemical characteristics | | FT3 (pmol/L) | 5.02 (4.08–6.17) | FT4 (pmol/L) | 14.32 (12.56–15.80) | TSH (mU/L) | 0.54 (0.04–1.01) | Eye symptoms and signs | | Proptosis (mm) | 21.19 ± 1.95 | Eyelid aperture (mm) | 12.31 ± 2.32 | Soft tissue involvements | | Absent | 0 (0%) | Minimal | 4 (30.8%) | Moderate | 8 (61.5%) | Severe | 1 (7.7%) | Diplopia (Bahn and Gorman’s score) | | Absent | 3 (23.1%) | Intermittent | 2 (15.4%) | Inconstant | 3 (23.1%) | Constant | 5 (38.4%) | Clinical Activity Score | 4 (3–5) | Ocular motility | | Elevation (degrees) | 22.53 ± 13.07 | Depression (degrees) | 45.85 ± 15.97 | Adduction (degrees) | 41.62 ± 7.79 | Abduction (degrees) | 37.31 ± 11.40 |
|
|
FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyrotropin.
|